Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6078-6086

  Bourquin, Carole ^a   Schmidt, Laura ^a   Lanz, Anna Lisa ^a   Storch, Bettina ^a   Wurzenberger, Cornelia ^a   Anz, David ^a   Sandholzer, Nadja ^a   Mocikat, Ralph ^c   Berger, Michael ^a,b   Poeck, Hendrik ^a,d   Hartmann, Gunther ^d   Hornung, Veit ^d   Endres, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; OLIGONUCLEOTIDE; RNA; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; OLIGORIBONUCLEOTIDES; POLY A; TOLL-LIKE RECEPTOR 7;

EID: 77954229780     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901594     Document Type: Article

References (60)

1. Takeuchi, O., and S. Akira. 2007. Recognition of viruses by innate immunity. Immunol. Rev. 220: 214-224.
2. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
3. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
4. Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, et al. 2006. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
5. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303: 1526-1529.
6. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
7. Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and R. E. Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc. Natl. Acad. Sci. USA 101: 17264-17269.
8. Pichlmair, A., O. Schulz, C. P. Tan, T. I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314: 997-1001.
9. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
10. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168: 4531-4537. (Pubitemid 34441357)
11. Krug, A., A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Tolllike receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31: 3026-3037.
12. Hornung, V., M. Guenthner-Biller, C. Bourquin, A. Ablasser, M. Schlee, S. Uematsu, A. Noronha, M. Manoharan, S. Akira, A. de Fougerolles, S. Endres, and G. Hartmann. 2005. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11: 263-270.
13. Bourquin, C., L. Schmidt, V. Hornung, C. Wurzenberger, D. Anz, N. Sandholzer, S. Schreiber, A. Voelkl, G. Hartmann, and S. Endres. 2007. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109: 2953-2960.
14. Terme, M., E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel. 2008. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9: 486-494.
15. Sobolev, O., P. Stern, A. Lacy-Hulbert, and R. O. Hynes. 2009. Natural killer cells require selectins for suppression of subcutaneous tumors. Cancer Res. 69: 2531-2539.
16. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
17. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3: 196-200.
18. Schon, M. P., and M. Schon. 2008. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27: 190-199.
19. + cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol. Immunother. 58: 575-587.
20. Broomfield, S. A., R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. Robinson, and A. J. Currie. 2009. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182: 5217-5224.
21. + T-cell-independent pathway for antitumor CTL induction. Blood 106: 338-344.
22. Crozat, K., K. Hoebe, S. Ugolini, N. A. Hong, E. Janssen, S. Rutschmann, S. Mudd, S. Sovath, E. Vivier, and B. Beutler. 2007. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 204: 853-863.
23. Neri, S., E. Mariani, A. Meneghetti, L. Cattini, and A. Facchini. 2001. Calceinacetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Diagn Lab. Immunol. 8: 1131-1135.
24. Glas, R., L. Franksson, C. Une, M. L. Eloranta, C. Ohlen, A. Orn, and K. Karre. 2000. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell-mediated responses. J. Exp. Med. 191: 129-138.
25. Durdik, J. M., B. N. Beck, E. A. Clark, and C. S. Henney. 1980. Characterization of a lymphoma cell variant selectively resistant to natural killer cells. J. Immunol. 125: 683-688.
26. Granucci, F., I. Zanoni, N. Pavelka, S. L. Van Dommelen, C. E. Andoniou, F. Belardelli, M. A. Degli Esposti, and P. Ricciardi-Castagnoli. 2004. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. 200: 287-295.
27. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5: 405-411.
28. Andoniou, C. E., S. L. van Dommelen, V. Voigt, D. M. Andrews, G. Brizard, C. Asselin-Paturel, T. Delale, K. J. Stacey, G. Trinchieri, and M. A. Degli-Esposti. 2005. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6: 1011-1019.
29. Akazawa, T., T. Ebihara, M. Okuno, Y. Okuda, M. Shingai, K. Tsujimura, T. Takahashi, M. Ikawa, M. Okabe, N. Inoue, et al. 2007. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA 104: 252-257.
30. Hart, O. M., V. Athie-Morales, G. M. O'Connor, and C. M. Gardiner. 2005. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J. Immunol. 175: 1636-1642.
31. Borg, C., M. Terme, J. Taieb, C. Menard, C. Flament, C. Robert, K. Maruyama, H. Wakasugi, E. Angevin, K. Thielemans, et al. 2004. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114: 379-388.
32. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
33. Dunn, G. P., A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri, J. D. Bui, M. S. Diamond, C. M. Koebel, C. Arthur, J. M. White, and R. D. Schreiber. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6: 722-729.
34. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3: 361-370.
35. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
36. Fehniger, T. A., S. F. Cai, X. Cao, A. J. Bredemeyer, R. M. Presti, A. R. French, and T. J. Ley. 2007. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26: 798-811.
37. Lucas, M., W. Schachterle, K. Oberle, P. Aichele, and A. Diefenbach. 2007. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26: 503-517.
38. Schleicher, U., J. Liese, I. Knippertz, C. Kurzmann, A. Hesse, A. Heit, J. A. Fischer, S. Weiss, U. Kalinke, S. Kunz, and C. Bogdan. 2007. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J. Exp. Med. 204: 893-906.
39. Martinez, J., X. Huang, and Y. Yang. 2008. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 180: 1592-1597.
40. Haas, T., J. Metzger, F. Schmitz, A. Heit, T. Muller, E. Latz, and H. Wagner. 2008. The DNA sugar backbone 2′-deoxyribose determines toll-like receptor 9 activation. Immunity 28: 315-323.
41. Yasuda, K., M. Rutz, B. Schlatter, J. Metzger, P. B. Luppa, F. Schmitz, T. Haas, A. Heit, S. Bauer, and H. Wagner. 2006. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur. J. Immunol. 36: 431-436.
42. Lan, T., E. R. Kandimalla, D. Yu, L. Bhagat, Y. Li, D. Wang, F. Zhu, J. X. Tang, M. R. Putta, Y. Cong, et al. 2007. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl. Acad. Sci. USA 104: 13750-13755.
43. Kato, H., O. Takeuchi, E. Mikamo-Satoh, R. Hirai, T. Kawai, K. Matsushita, A. Hiiragi, T. S. Dermody, T. Fujita, and S. Akira. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205: 1601-1610.
44. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
45. Katze, M. G., M. Wambach, M. L. Wong, M. Garfinkel, E. Meurs, K. Chong, B. R. Williams, A. G. Hovanessian, and G. N. Barber. 1991. Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNAactivated, 68,000-Mr protein kinase in a cell-free system. Mol. Cell Biol. 11: 5497-5505.
46. Kanneganti, T. D., M. Body-Malapel, A. Amer, J. H. Park, J. Whitfield, L. Franchi, Z. F. Taraporewala, D. Miller, J. T. Patton, N. Inohara, and G. Nunez. 2006. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281: 36560-36568.
47. Alter, G., T. J. Suscovich, N. Teigen, A. Meier, H. Streeck, C. Brander, and M. Altfeld. 2007. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J. Immunol. 178: 7658-7666. (Pubitemid 46898036)
48. Sawaki, J., H. Tsutsui, N. Hayashi, K. Yasuda, S. Akira, T. Tanizawa, and K. Nakanishi. 2007. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int. Immunol. 19: 311-320.
49. Girart, M. V., M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner. 2007. Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179: 3472-3479.
50. Berger, M., A. Ablasser, S. Kim, I. Bekeredjian-Ding, T. Giese, S. Endres, V. Hornung, and G. Hartmann. 2009. TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. J. Immunother. 32: 262-271.
51. Gorski, K. S., E. L. Waller, J. Bjornton-Severson, J. A. Hanten, C. L. Riter, W. C. Kieper, K. B. Gorden, J. S. Miller, J. P. Vasilakos, M. A. Tomai, and S. S. Alkan. 2006. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol. 18: 1115-1126.
52. Kanneganti, T. D., N. Ozoren, M. Body-Malapel, A. Amer, J. H. Park, L. Franchi, J. Whitfield, W. Barchet, M. Colonna, P. Vandenabeele, et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233-236.
53. Kijima, M., T. Yamaguchi, C. Ishifune, Y. Maekawa, A. Koyanagi, H. Yagita, S. Chiba, K. Kishihara, M. Shimada, and K. Yasutomo. 2008. Dendritic cellmediated NK cell activation is controlled by Jagged2-Notch interaction. Proc. Natl. Acad. Sci. USA 105: 7010-7015.
54. Qian, C., X. Jiang, H. An, Y. Yu, Z. Guo, S. Liu, H. Xu, and X. Cao. 2006. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108: 2307-2315.
55. Gerosa, F., A. Gobbi, P. Zorzi, S. Burg, F. Briere, G. Carra, and G. Trinchieri. 2005. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 174: 727-734.
56. Dalod, M., T. Hamilton, R. Salomon, T. P. Salazar-Mather, S. C. Henry, J. D. Hamilton, and C. A. Biron. 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon α/β. J. Exp. Med. 197: 885-898.
57. Koka, R., P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Cutting edge: murine dendritic cells require IL-15Rα to prime NK cells. J. Immunol. 173: 3594-3598.
58. Zhou, H., Y. Luo, C. D. Kaplan, J. A. Kruger, S. H. Lee, R. Xiang, and R. A. Reisfeld. 2006. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood 107: 3251-3257.
59. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.
60. Poeck, H., R. Besch, C. Maihoefer, M. Renn, D. Tormo, S. S. Morskaya, S. Kirschnek, E. Gaffal, J. Landsberg, J. Hellmuth, et al. 2008. 5′-TriphosphatesiRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14: 1256-1263.